Novo Nordisk Challenges Pfizer in Obesity Biotech Bid
Novo Nordisk, led by new CEO Maziar Mike Doustdar, has made a surprise move to challenge Pfizer’s ownership of Metsera, an emerging obesity biotech. The Danish pharma is offering $8.5 billion for the company, which had previously accepted nearly $5 billion from Pfizer just months ago. Pfizer, however, seems livid and accuses Novo Nordisk of … Read more